Impact of KRAS mutation subtypes on morphological heterogeneity and immune landscape in surgically treated lung adenocarcinoma.

Transl Lung Cancer Res · 2025 · PMC12261357 · PMID 40673097

Europe PMC DOI

hedged sentences

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP=0.14not close (p > 0.1)

As shown in Figure S1 , patients with KRAS wild-type tumors tended to have better survival outcomes than those with specific KRAS mutations, yet differences in median OS did not reach statistical significance (P=0.14).

also in 111,027 other papers

borderline significantno p-value reported

39 months, respectively; P=0.08), with borderline significant statistical outcomes.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.